Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 876

2.

Treatment options for vancomycin-resistant enterococcal infections.

Linden PK.

Drugs. 2002;62(3):425-41. Review.

PMID:
11827558
3.

Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus.

Maclayton DO, Hall RG 2nd.

Ann Pharmacother. 2007 Feb;41(2):235-44. Review.

PMID:
17299012
4.

Newer treatment options for skin and soft tissue infections.

Raghavan M, Linden PK.

Drugs. 2004;64(15):1621-42. Review.

PMID:
15257625
6.

Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.

Florescu I, Beuran M, Dimov R, Razbadauskas A, Bochan M, Fichev G, Dukart G, Babinchak T, Cooper CA, Ellis-Grosse EJ, Dartois N, Gandjini H; 307 Study Group..

J Antimicrob Chemother. 2008 Sep;62 Suppl 1:i17-28. doi: 10.1093/jac/dkn250.

7.
8.

Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.

Zhanel GG, Lam A, Schweizer F, Thomson K, Walkty A, Rubinstein E, Gin AS, Hoban DJ, Noreddin AM, Karlowsky JA.

Am J Clin Dermatol. 2008;9(4):245-54. Review.

PMID:
18572975
9.

Dalbavancin: a review for dermatologists.

Scheinfeld N.

Dermatol Online J. 2006 May 30;12(4):6. Review.

PMID:
17083861
10.

Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.

Zhanel GG, Sniezek G, Schweizer F, Zelenitsky S, Lagacé-Wiens PR, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA.

Drugs. 2009;69(7):809-31. doi: 10.2165/00003495-200969070-00003. Review.

PMID:
19441869
13.
14.

Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options.

Welte T, Pletz MW.

Int J Antimicrob Agents. 2010 Nov;36(5):391-400. doi: 10.1016/j.ijantimicag.2010.06.045. Review.

PMID:
20724119
15.

Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies.

Kosowska-Shick K, Clark C, Pankuch GA, McGhee P, Dewasse B, Beachel L, Appelbaum PC.

Antimicrob Agents Chemother. 2009 Oct;53(10):4217-24. doi: 10.1128/AAC.00742-09.

16.

New antimicrobial agents as therapy for resistant gram-positive cocci.

Lentino JR, Narita M, Yu VL.

Eur J Clin Microbiol Infect Dis. 2008 Jan;27(1):3-15. Review.

PMID:
17899228
17.

Treatment options for multidrug-resistant bacteria.

Giamarellou H.

Expert Rev Anti Infect Ther. 2006 Aug;4(4):601-18. Review.

PMID:
17009940
18.

Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci.

Eliopoulos GM.

Eur J Clin Microbiol Infect Dis. 2005 Dec;24(12):826-31. Review.

PMID:
16315008
19.
20.

The need for new therapeutic agents: what is the pipeline?

Shah PM.

Clin Microbiol Infect. 2005 May;11 Suppl 3:36-42. Review.

PMID:
15900655
Items per page

Supplemental Content

Support Center